Key Takeaways MRK to acquire Verona Pharma for $10B, adding FDA-approved COPD drug Ohtuvayre to its portfolio. Ohtuvayre offers dual PDE3/4 inhibition, combining bronchodilation and anti-inflammatory effects. The deal supports MRK's diversification as Keytruda faces patent expiry and increased competition. Earlier this week, Merck (MRK) announced a definitive agreement to acquire Verona Pharma (VRNA) for approximately $10 billion. The deal will add Verona’s Ohtuvayre, approved for the maintenance treatmen ...

【DT新材料】 获悉，近日， 关于 内蒙古双欣环保材料股份有限公司 年产 15万吨 乙烯法醋酸乙烯及 6万吨 特种聚乙烯醇项目环评 第二次公示。 · 政策发展 · 市场分析 · 投融资 · 供应链 · Al赋能 2025"新塑奖"评选颁奖盛典 内蒙古双欣环保材料股份有限公司 成立于2009年6月，注册资本86,000万元。双欣环保是一家专业从事聚乙烯醇（PVA）、聚乙烯醇特种纤维、醋酸乙 烯（VAC）、碳化钙（电石）等PVA产业链上下游产品的研发、生产、销售的高新技术企业，拥有聚乙烯醇全产业链布局。其中， 电石作为化工"基 石"，主要用于生产乙炔进而合成PVC、PVA、BDO等重要化工材料 ，是有机化学工业上游的基础性原材料。 说明： 本文部分素材来自于 内蒙古双欣环保材料股份有限公司 及网络公开信息，由作者重新编写，系作者个人观点，本平台发布仅为了传达一种不同观点，不代表对该观点赞同或支持。如果有 任何问题，请联系我们：15355132586（微信号：dtmaterial） | 全体大会 高分子产业年会(全体大会) 项目 总投资 201173.59万元 ， 建设规模包括 15万吨/年乙烯法醋酸乙烯(VAC) ...

Key Takeaways MRK faces major headwinds as Keytruda, its top seller, nears the loss of exclusivity in 2028. Gardasil sales dropped 40% in Q1 2025 due to weak China demand, despite strength in other regions. MRK expects IRA's Medicare drug pricing to impact Januvia in 2026 and Keytruda starting in 2028.Merck (MRK) is expected to face several hurdles over the next few years that could affect its long-term growth trajectory, starting with the anticipated loss of exclusivity of its blockbuster PD-L1 inhibitor ...

Group 1: Macro Insights - The recent tariff increase by the US affects 14 countries, including Japan, South Korea, and ASEAN nations, with a significant adjustment in tariffs on Vietnam to 20% and 40% on transshipment trade [2] - The overall US tariff level is expected to remain between 15-20%, while tariffs on China are likely to stay between 30-40%, with a stronger focus on specific categories [2] Group 2: Market Trends - The market is currently in a volatile phase, with structural highlights present but facing resistance; trading funds remain active, while foreign passive allocation shows significant inflows [3] - The net outflow of broad-based ETFs reached a new high since March, indicating potential market instability [3] Group 3: Fixed Income and Asset Correlation - Changes in global order have altered asset pricing logic, leading to a unique positive correlation between US stocks, the dollar, and bonds, resulting in increased volatility [4] - The domestic stock-bond negative correlation provides a favorable environment for diversified asset allocation [4] Group 4: Machinery Industry - Excavator sales in June reached 18,800 units, a year-on-year increase of 13.3%, with exports growing by 19% [5] - The growth in second-hand excavator exports is expected to stimulate domestic replacement demand, benefiting leading companies in the sector [5] Group 5: Agriculture Sector - The "anti-involution" policy in the pig farming industry is expected to release inventory and positively impact pig prices in the autumn and winter seasons [7] - Major pig farming companies are adjusting their production strategies, which may enhance overall profitability in the long term [7] Group 6: Chemical and Oil Industry - The capital expenditure growth rate in the chemical and oil sector is declining, indicating a potential turning point in industry prosperity [9] - The demand recovery in downstream chemical products is anticipated alongside a reduction in capital expenditure, which may lead to a recovery in the second half of 2025 [9] Group 7: Telecommunications Industry - The global telecommunications industry is experiencing steady growth, driven by demand in emerging markets and increasing ARPU in North America [10] - The integration of AI technologies is expected to bring transformative opportunities to the telecommunications sector [10] Group 8: Electric Power and New Energy - The recent policy from the National Development and Reform Commission aims to promote the construction of high-power charging facilities, which is expected to enhance the profitability of equipment manufacturers [11] - The goal is to have over 100,000 high-power charging facilities nationwide by the end of 2027, indicating strong policy support for the sector [11] Group 9: Company Performance - Shengquan Group expects a net profit of 491-513 million yuan for the first half of 2025, reflecting a year-on-year increase of 48%-55% [12] - Industrial Fulian anticipates a net profit of 11.958-12.158 billion yuan for the first half of 2025, marking a growth of 36.84%-39.12% [14]

Investment Rating - The report maintains an "Accumulate" rating for the company [6][4]. Core Views - The company is expected to achieve a net profit attributable to shareholders of 235-265 million RMB in the first half of 2025, representing a year-on-year increase of 81%-104% [1]. - The second quarter is projected to yield a net profit of 117-147 million RMB, reflecting a year-on-year growth of 42%-79% [1]. - The company benefits from a favorable competitive landscape in PVA and successful ramp-up of new materials such as PVA optical films [1]. Summary by Sections Financial Performance - The company anticipates a significant increase in net profit for H1 2025, with a forecast of 2.35-2.65 billion RMB, and a non-recurring net profit of 2.23-2.53 billion RMB, marking growth of 89%-115% year-on-year [1]. - For Q2 2025, the expected net profit is 1.17-1.47 billion RMB, with a non-recurring net profit of 1.06-1.36 billion RMB, indicating a year-on-year increase of 46%-87% [1]. Cost and Pricing Analysis - The average price of PVA in Q2 was reported at 11,038 RMB/ton, with a price difference from acetylene at 5,524 RMB/ton, showing a year-on-year decrease of 8% and 428 RMB/ton respectively [2]. - The cost side has improved significantly, with Q2 prices for coal, acetic acid, and acetylene showing declines of 25%, 20%, and 7% year-on-year [2]. Market Outlook - The report suggests that the trend of cost improvement for PVA may continue, supported by a favorable supply-demand balance and the absence of new domestic production capacity [3]. - The company is expected to increase its global market share in PVA, with exports rising by 13% year-on-year in the first five months of 2025 [3]. Profit Forecast and Valuation - The forecast for net profit attributable to shareholders for 2025-2027 is set at 530 million, 670 million, and 770 million RMB respectively, with corresponding EPS of 0.25, 0.32, and 0.37 RMB [4]. - The target price is maintained at 5.50 RMB, based on a 22x PE ratio for 2025 [4].

Group 1 - The company forecasts a net profit of between 235 million yuan and 265 million yuan, representing an increase of 105.41 million yuan to 135.41 million yuan compared to the same period last year, with a year-on-year growth of 89.37% to 114.85% [1] - The previous year's net profit attributable to shareholders was 129.59 million yuan, with a basic earnings per share of 0.06 yuan [1] - The main reasons for the profit increase include a rise in sales and prices of key products such as Polyvinyl Alcohol (PVA), vinyl acetate, and methyl acetate [1] Group 2 - The company has seen a significant increase in export volumes, with PVA exports growing by over 40%, methyl acetate by over 30%, and VAE emulsion by over 210% [2] - The company is enhancing its R&D investment to overcome technical barriers in high-end products, transitioning from a "cost leadership" to a "technology leadership" strategy, which has improved operational performance [2] - The gross profit margins for products like PVA and polyester chips have increased, enhancing overall profitability [2]

本周化工市场综述 本周市场震荡向上，其中申万化工指数上涨 0.8%，跑输沪深 300 指数 0.74%。标的方面，本周 AI 材料标的表现 亮眼，比如：东材科技、中材科技、长海股份，除此之外，有边际变化的标的也有较佳表现，比如：久日新材、广 信材料、国恩股份、苏利股份，当下市场会给予有边际变化以及存在新增长曲线的公司正反馈，这类风格或将继续 强化。估值方面，当前板块的赔率依然较高，其中板块 PB 历史分位数为 20%，PE 历史分位数为 71%。化工行业，主 要关注四大事件，一是本周美国商务部工业与安全局发出的一纸正式通知，终结了自 5 月底以来持续困扰中美能源 贸易市场的乙烷出口风波，万华化学和卫星化学乙烷利空解除；二是巴斯夫动物营养业务的重要产品露他维®A 1000 NXT （Lutavit® A 1000 NXT）不可抗力声明正式解除；三是国内新材料产品持续突破，包括阿科力 5000 吨 COC 正 式投产以及上海洁达尼龙材料有限公司 12 万吨/年己二胺装置一次投料开车成功；四是 SABIC 确认将永久关停位于 英国英格兰泰恩赛德地区的烯烃 6 号裂解装置，该装置乙烯年产能为 86.5 万吨，丙烯年产 ...

Core Insights - Novo Nordisk (NVO) has achieved significant growth driven by the success of its semaglutide-based therapies, Wegovy and Ozempic, while also diversifying into rare blood disorders [1][9] Product Portfolio - Key marketed hemophilia therapies include NovoSeven and Esperoct, contributing incremental revenues [2] - Alhemo has recently been approved in the EU for hemophilia A or B with inhibitors, although it is not yet approved in the U.S. [3] - The company is evaluating Mim8 in a late-stage program for hemophilia A, with regulatory submission anticipated in 2025 [4] Competitive Landscape - Eli Lilly (LLY) generates substantial revenue from its tirzepatide medicines and has a diverse product range across various therapeutic areas, including oncology and immunology [5] - Merck (MRK) is also expanding its therapeutic reach beyond its flagship oncology drug Keytruda, with new products expected to generate significant long-term revenues [6] Stock Performance and Valuation - Year-to-date, Novo Nordisk shares have declined by 19.6%, underperforming the industry and the S&P 500 [7][8] - The company's shares trade at a forward price/earnings ratio of 16.31, higher than the industry average of 15.09, but below its five-year mean of 29.25 [10] Earnings Estimates - Earnings estimates for 2025 have improved from $3.89 to $3.93 per share, while 2026 estimates have decreased from $4.76 to $4.58 [15] - The stock's return on equity is 80.95%, significantly higher than the industry average of 33.55% [18]

化学原料行业近一年市场表现 资料来源：最闻 相关报告： 补贴，推动风电行业维持高速发展-新材 料周报（250616-0620） 2025.6.24 打印新需求，核心耗材 PLA 迎来发展新 机-新材料周报（250609-0613）2025.6.17 冀泳洁 博士 执业登记编码：S0760523120002 邮箱：jiyongjie@sxzq.com 王锐 执业登记编码：S0760524090001 申向阳 邮箱：shenxiangyang@sxzq.com 新材料 新材料周报（250623-0627） 领先大市-B(维持) 工信部印发绿色低碳重要实施方案，生物航煤价格持续上涨 2025 年 7 月 3 日 行业研究/行业周报 二级市场表现 市场与板块表现：本周新材料板块上涨。新材料指数涨幅为 5.12%，跑输创 业板指 0.57%。近五个交易日，合成生物指数上涨 2.30%，半导体材料上涨 4.09%， 电子化学品上涨 5.20%，可降解塑料上涨 2.93%，工业气体上涨 3.03%，电池化 学品上涨 9.13%。 产业链周度价格跟踪（括号为周环比变化） 氨基酸：缬氨酸(14200 元/吨，0.35%)、精氨 ...

Financial Performance and Guidance - Ligand's total revenue guidance for 2024 is $160-$165 million[21], with royalty revenue expected to be $105-108 million[22], representing a 27% increase from 2023[30] - The company anticipates adjusted EPS of $550-$570 in 2024[22], a 38% growth[30] - For 2025, Ligand forecasts total revenue of $180-$200 million[34], with royalty revenue growing by 30% over 2024[35] - Ligand projects royalty receipts to grow at a CAGR of 22% from 2024 to 2029[24, 40] Investment and Portfolio Activity - Ligand deployed $192 million across 8 different investments in 2024[21] - The company's Q4 pipeline includes over 30 actionable opportunities, representing over $1 billion of potential investments[61] - Ligand acquired Apeiron Biologics in July 2024 for approximately $100 million, gaining rights to Qarziba royalties[70] Key Products and Platforms - Ligand's Captisol platform is used in 16 approved products[99, 104] - Verona's Ohtuvayre, in which Ligand has royalty rights, achieved over $11 million in sales in the first 4 months following approval[75] - Travere's Filspari generated $356 million in Q3 2024, with 31% growth from Q2 2024[80] - Merck's Capvaxive, another royalty asset for Ligand, protects against strains that cause 84% of invasive pneumococcal disease[88]